---
schema_version: "secwatch.filing_event.v1"
accession: "0000875320-26-000147"
form_type: "8-K"
ticker: "VRTX"
cik: "0000875320"
company_name: "VERTEX PHARMACEUTICALS INC / MA"
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:18:57.371142+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Vertex completes BLA submission for povetacicept in IgAN with priority review

## Summary
- Submitted rolling Biologics Licensing Application to FDA for povetacicept to treat IgAN in adults.
- Used a priority review voucher, reducing expected FDA review to 6 months from typical 10 months.
- Submission seeks potential accelerated approval; no decision or timeline for acceptance yet.
- Company notes forward-looking statements and risks including regulatory approval uncertainty.

## SEC filing metadata
- accession: 0000875320-26-000147
- form_type: 8-K
- ticker: VRTX
- cik: 0000875320
- company_name: VERTEX PHARMACEUTICALS INC / MA
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/875320/000087532026000147/0000875320-26-000147-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/875320/000087532026000147/vrtx-20260331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000875320-26-000147
- JSON: https://secwatch.observer/filing/0000875320-26-000147.json
- Plain text: https://secwatch.observer/filing/0000875320-26-000147.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.